These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 15827276)
21. Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. Borrmann S; Faucher JF; Bagaphou T; Missinou MA; Binder RK; Pabisch S; Rezbach P; Matsiegui PB; Lell B; Miller G; Kremsner PG Clin Infect Dis; 2003 Dec; 37(11):1441-7. PubMed ID: 14614665 [TBL] [Abstract][Full Text] [Related]
22. Atovaquone-proguanil for prophylaxis and treatment of malaria. Marra F; Salzman JR; Ensom MH Ann Pharmacother; 2003 Sep; 37(9):1266-75. PubMed ID: 12921511 [TBL] [Abstract][Full Text] [Related]
23. [symbol: see text] Atovaquone + proguanil for malaria prophylaxis. Drug Ther Bull; 2001 Oct; 39(10):73-5. PubMed ID: 11706518 [TBL] [Abstract][Full Text] [Related]
24. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Kain KC; Shanks GD; Keystone JS Clin Infect Dis; 2001 Jul; 33(2):226-34. PubMed ID: 11418883 [TBL] [Abstract][Full Text] [Related]
25. Parallel evolution of adaptive mutations in Plasmodium falciparum mitochondrial DNA during atovaquone-proguanil treatment. Musset L; Le Bras J; Clain J Mol Biol Evol; 2007 Aug; 24(8):1582-5. PubMed ID: 17488741 [TBL] [Abstract][Full Text] [Related]
26. [Tolerance and efficacy of atovaquone-proguanil for the treatment of paediatric imported Plasmodium falciparum malaria in France: clinical practice in a university hospital in Paris]. Blondé R; Naudin J; Bigirimana Z; Holvoet L; Fenneteau O; Vitoux C; Bourdon O; Angoulvant F; Lorrot M; D'Ortenzio E; Bourrillon A; Le Bras J; Matheron S; Faye A Arch Pediatr; 2008 Mar; 15(3):245-52. PubMed ID: 18321692 [TBL] [Abstract][Full Text] [Related]
27. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Camus D; Djossou F; Schilthuis HJ; Høgh B; Dutoit E; Malvy D; Roskell NS; Hedgley C; De Boever EH; Miller GB; Clin Infect Dis; 2004 Jun; 38(12):1716-23. PubMed ID: 15227617 [TBL] [Abstract][Full Text] [Related]
28. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Wichmann O; Muehlen M; Gruss H; Mockenhaupt FP; Suttorp N; Jelinek T Malar J; 2004 Jun; 3():14. PubMed ID: 15186499 [TBL] [Abstract][Full Text] [Related]
29. [Clinical studies using the combination atovaquone-proguanil as malaria prophylaxis in non-immune adult and child travelers]. Camus D; Dutoit E; Masson V; Inglebert P; Delhaes L Med Trop (Mars); 2002; 62(3):225-8. PubMed ID: 12244915 [TBL] [Abstract][Full Text] [Related]
30. [Experience with the combination atovaquone-proguanil in the treatment of uncomplicated Plasmodium falciparum malaria--report of 112 cases]. Malvy D; Djossou F; Vatan R; Pistone T; Etienne G; Longy-Boursier M; Le Bras M Med Trop (Mars); 2002; 62(3):229-31. PubMed ID: 12244916 [TBL] [Abstract][Full Text] [Related]
31. Atovaquone-proguanil for falciparum malaria in the Philippines. Watt G J Infect Dis; 2000 Jan; 181(1):405. PubMed ID: 10608798 [No Abstract] [Full Text] [Related]
32. [Malarone: newcomer in the treatment of malaria]. Touze JE; Fourcade L Med Trop (Mars); 1997; 57(3):225-7. PubMed ID: 9513142 [No Abstract] [Full Text] [Related]
33. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Edstein MD; Kotecka BM; Anderson KL; Pombo DJ; Kyle DE; Rieckmann KH; Good MF Antimicrob Agents Chemother; 2005 Oct; 49(10):4421-2. PubMed ID: 16189139 [No Abstract] [Full Text] [Related]
34. Plasmodium falciparum outwits Malarone, protector of travellers. Crabb C Bull World Health Organ; 2003; 81(5):382-3. PubMed ID: 12856058 [No Abstract] [Full Text] [Related]
35. Atovaquone/Proguanil (Malarone) for malaria. Med Lett Drugs Ther; 2000 Nov; 42(1093):109-11. PubMed ID: 11093830 [No Abstract] [Full Text] [Related]
36. In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand. Khositnithikul R; Tan-Ariya P; Mungthin M Malar J; 2008 Jan; 7():23. PubMed ID: 18226262 [TBL] [Abstract][Full Text] [Related]
37. Atovaquone-proguanil (malarone): an effective treatment for uncomplicated Plasmodium falciparum malaria in travelers from Denmark. Thybo S; Gjorup I; Ronn AM; Meyrowitsch D; Bygberg IC J Travel Med; 2004; 11(4):220-3. PubMed ID: 15541224 [TBL] [Abstract][Full Text] [Related]
38. Molecular epidemiology of malaria in Cameroon. XVII. Baseline monitoring of atovaquone-resistant Plasmodium falciparum by in vitro drug assays and cytochrome b gene sequence analysis. Basco LK Am J Trop Med Hyg; 2003 Aug; 69(2):179-83. PubMed ID: 14506774 [TBL] [Abstract][Full Text] [Related]
39. Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial. Bouchaud O; Monlun E; Muanza K; Fontanet A; Scott T; Goetschel A; Chulay JD; Le Bras J; Danis M; Le Bras M; Coulaud JP; Gentilini M Am J Trop Med Hyg; 2000; 63(5-6):274-9. PubMed ID: 11421377 [TBL] [Abstract][Full Text] [Related]
40. Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola. Pimentel S; Nogueira F; Benchimol C; Quinhentos V; Bom J; Varandas L; do Rosário V; Bernardino L Malar J; 2006 Apr; 5():30. PubMed ID: 16597338 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]